Though canine pancreatic neuroendocrine neoplasms (PanNENs) have been proposed as a mannequin for the counterpart human neoplasms, the kind or grade of human PanNEN that they resemble is unclear. PanNENs in animals are categorised as adenoma or carcinoma, whereas in people they’re categorised as pancreatic neuroendocrine tumour (PanNET) if well-differentiated, or as pancreatic neuroendocrine carcinoma (PanNEC) if poorly differentiated.
We evaluated 16 canine main PanNENs and two metastases histologically and immunohistochemically, and graded them utilizing the animal and human grading techniques. All neoplasms had native or vascular invasion and had been categorised as pancreatic islet cell carcinomas in accordance with the present WHO classification. The Ki-67 index was low in all instances (0.01-1.50%). All had cytoplasmic expression of synaptophysin and insulin however had been immunonegative for glucagon, confirming a purposeful analysis of canine insulinoma. Membranous expression of SSTR2A and nuclear expression of ATRX, however no p53 expression, was present in all neoplasms.
One main tumour was recognized as a combined neuroendocrine-non-neuroendocrine neoplasm, which is the primary report of this neoplasm in canines. The opposite 15 main tumours and each metastatic tumours had been graded as PanNET G1, in accordance with the human WHO classification. We conclude that canine PanNENs share well-differentiated histomorphology, SSTR2A expression and absence of nuclear p53 immunolabelling with human PanNETs G1. Nevertheless, they differ in ATRX gene expression and performance, and appear to have a worse prognosis than human PanNETs G1, though their typically low Ki-67 index precludes extra exact evaluation of prognosis. Membranous SSTR2A expression renders canine PanNENs doubtlessly amenable to remedy with somatostatin analogues or SSTR focused in-vivo imaging strategies.
Gene Augmentation and Enhancing to Enhance TCR Engineered T Cell Remedy in opposition to Stable Tumors
Latest developments in gene engineering applied sciences have drastically improved the therapeutic remedy choices for most cancers sufferers. The usage of efficient chimeric antigen receptor T (CAR-T) cells and recombinant T cell receptor engineered T (rTCR-T) cells has entered the clinic for remedy of hematological malignancies with promising outcomes. Nevertheless, additional fine-tuning, to enhance performance and security, is important to use these methods for the remedy of strong tumors. The immunosuppressive microenvironment, the encompassing stroma, and the tumor heterogeneity usually leads to poor T cell reactivity, performance, and a diminished infiltration charges, hampering the efficacy of the remedy.
The main focus of this assessment is on current advances in rTCR-T cell remedy, to enhance each performance and security, for potential remedy of strong tumors and offers an summary of ongoing scientific trials. In addition to collection of the suitable tumor related antigen, environment friendly supply of an optimized recombinant TCR transgene into the T cells, together with gene modifying methods eliminating the endogenous TCR expression and disrupting particular inhibitory pathways may enhance adoptively transferred T cells. Armoring the rTCR-T cells with particular cytokines and/or chemokines and their receptors, or concentrating on the tumor stroma, can improve the infiltration price of the immune cells inside the strong tumors.
Alternatively, scientific “off-tumor/on-target” toxicities are nonetheless a significant potential threat and might result in extreme antagonistic occasions. Incorporation of security switches in rTCR-T cells can assure further security. Latest scientific trials present encouraging knowledge and emphasize the relevance of gene remedy and gene modifying instruments for potential remedy of strong tumors.
Do Canine Pancreatic Neuroendocrine Neoplasms Resemble Human Pancreatic Neuroendocrine Tumours? A Comparative Morphological and Immunohistochemical Investigation
Lengthy-term oncological outcomes of laparoscopic gastrectomy for grossly early gastric most cancers-mimicking superior gastric most cancers: Propensity rating matching evaluation
Laparoscopic gastrectomy grew to become an choice within the remedy of early gastric most cancers (EGC) in scientific observe. Nevertheless, whether or not laparoscopic surgical procedure for grossly EGC-mimicking superior gastric most cancers (AGC) sufferers is oncologically secure long-term remains to be controversial.We retrospectively analyzed 472 sufferers with AGC who had been recognized as scientific EGC. Sufferers acquired laparoscopic or open gastrectomy with customary lymph node (LN) dissection from January 2007 to February 2015. We used a 1:Three propensity rating matching technique for the evaluation. The matching elements had been age, intercourse, physique mass index, American Society of Anesthesiologists rating and pathologic stage.
After the matching course of, we evaluated the 5-year general survival and the cumulative incidence curve of recurrence.The entire analyzed sufferers had been pathologically recognized with AGC after surgical procedure (grossly EGC-mimicking AGC). The median (vary) period of follow-up was 58.0 (0-132) months. After propensity rating matching, 31.5% of sufferers within the laparoscopy group had D1+ LN dissection and 99.2% of sufferers within the open group had D2 LN dissection. The 5-year general survival price between the laparoscopy (n = 92) and open teams (n = 244) weren’t considerably totally different.
) CA125 Cancer Antigen (Ovarian Cancer) |
|
MBS651704-50KUnits |
MyBiosource |
50KUnits |
EUR 900 |
CA125 Cancer Antigen (Ovarian Cancer) |
|
MBS651704-5x50KUnits |
MyBiosource |
5x50KUnits |
EUR 3905 |
 (AP)) CA125 Cancer Antigen (Ovarian Cancer) (AP) |
|
MBS6260289-01mL |
MyBiosource |
0.1mL |
EUR 970 |
CA125 Cancer Antigen (Ovarian Cancer) (AP) |
|
MBS6260289-5x01mL |
MyBiosource |
5x0.1mL |
EUR 4220 |
 (PE)) CA125 Cancer Antigen (Ovarian Cancer) (PE) |
|
MBS6262840-01mL |
MyBiosource |
0.1mL |
EUR 970 |
CA125 Cancer Antigen (Ovarian Cancer) (PE) |
|
MBS6262840-5x01mL |
MyBiosource |
5x0.1mL |
EUR 4220 |
 (HRP)) CA125 Cancer Antigen (Ovarian Cancer) (HRP) |
|
MBS6262329-01mL |
MyBiosource |
0.1mL |
EUR 970 |
CA125 Cancer Antigen (Ovarian Cancer) (HRP) |
|
MBS6262329-5x01mL |
MyBiosource |
5x0.1mL |
EUR 4220 |
 (APC)) CA125 Cancer Antigen (Ovarian Cancer) (APC) |
|
MBS6260800-01mL |
MyBiosource |
0.1mL |
EUR 970 |
CA125 Cancer Antigen (Ovarian Cancer) (APC) |
|
MBS6260800-5x01mL |
MyBiosource |
5x0.1mL |
EUR 4220 |
 (FITC)) CA125 Cancer Antigen (Ovarian Cancer) (FITC) |
|
MBS6261819-01mL |
MyBiosource |
0.1mL |
EUR 970 |
CA125 Cancer Antigen (Ovarian Cancer) (FITC) |
|
MBS6261819-5x01mL |
MyBiosource |
5x0.1mL |
EUR 4220 |
 (Biotin)) CA125 Cancer Antigen (Ovarian Cancer) (Biotin) |
|
MBS6261311-01mL |
MyBiosource |
0.1mL |
EUR 970 |
CA125 Cancer Antigen (Ovarian Cancer) (Biotin) |
|
MBS6261311-5x01mL |
MyBiosource |
5x0.1mL |
EUR 4220 |
) CA125 Cancer Antigen, B Domain (Ovarian Cancer) |
|
MBS608535-1mg |
MyBiosource |
1mg |
EUR 1135 |
CA125 Cancer Antigen, B Domain (Ovarian Cancer) |
|
MBS608535-5x1mg |
MyBiosource |
5x1mg |
EUR 4955 |
) CA125 Cancer Antigen, A Domain (Ovarian Cancer) |
|
MBS633047-01mg |
MyBiosource |
0.1mg |
EUR 375 |
CA125 Cancer Antigen, A Domain (Ovarian Cancer) |
|
MBS633047-1mg |
MyBiosource |
1mg |
EUR 1135 |
CA125 Cancer Antigen, A Domain (Ovarian Cancer) |
|
MBS633047-5x1mg |
MyBiosource |
5x1mg |
EUR 4955 |
 (MaxLight 490)) CA125 Cancer Antigen (Ovarian Cancer) (MaxLight 490) |
|
MBS6263862-01mL |
MyBiosource |
0.1mL |
EUR 970 |
CA125 Cancer Antigen (Ovarian Cancer) (MaxLight 490) |
|
MBS6263862-5x01mL |
MyBiosource |
5x0.1mL |
EUR 4220 |
 (MaxLight 550)) CA125 Cancer Antigen (Ovarian Cancer) (MaxLight 550) |
|
MBS6264373-01mL |
MyBiosource |
0.1mL |
EUR 970 |
CA125 Cancer Antigen (Ovarian Cancer) (MaxLight 550) |
|
MBS6264373-5x01mL |
MyBiosource |
5x0.1mL |
EUR 4220 |
 (MaxLight 650)) CA125 Cancer Antigen (Ovarian Cancer) (MaxLight 650) |
|
MBS6264884-01mL |
MyBiosource |
0.1mL |
EUR 970 |
CA125 Cancer Antigen (Ovarian Cancer) (MaxLight 650) |
|
MBS6264884-5x01mL |
MyBiosource |
5x0.1mL |
EUR 4220 |
 (MaxLight 750)) CA125 Cancer Antigen (Ovarian Cancer) (MaxLight 750) |
|
MBS6265395-01mL |
MyBiosource |
0.1mL |
EUR 970 |
CA125 Cancer Antigen (Ovarian Cancer) (MaxLight 750) |
|
MBS6265395-5x01mL |
MyBiosource |
5x0.1mL |
EUR 4220 |
 (MaxLight 405)) CA125 Cancer Antigen (Ovarian Cancer) (MaxLight 405) |
|
MBS6263351-01mL |
MyBiosource |
0.1mL |
EUR 970 |
CA125 Cancer Antigen (Ovarian Cancer) (MaxLight 405) |
|
MBS6263351-5x01mL |
MyBiosource |
5x0.1mL |
EUR 4220 |
 Protein) Human Cancer Antigen CA125 (Ovarian Cancer) Protein |
|
abx061590-100kU |
Abbexa |
100 kU |
EUR 1446 |
|
|
Human Cancer Antigen CA125 (Ovarian Cancer) Protein |
|
abx061590-100g |
Abbexa |
100 µg |
Ask for price |
Human Cancer Antigen CA125 (Ovarian Cancer) Protein |
|
abx061590-10g |
Abbexa |
10 µg |
EUR 1537.5 |
Human Cancer Antigen CA125 (Ovarian Cancer) Protein |
|
abx061590-50g |
Abbexa |
50 µg |
Ask for price |
 (Glycerol Free)) CA125 Cancer Antigen (Ovarian Cancer) (Glycerol Free) |
|
MBS651691-50KUnits |
MyBiosource |
50KUnits |
EUR 885 |
CA125 Cancer Antigen (Ovarian Cancer) (Glycerol Free) |
|
MBS651691-5x50KUnits |
MyBiosource |
5x50KUnits |
EUR 3825 |
 (AP)) CA125 Cancer Antigen, A Domain (Ovarian Cancer) (AP) |
|
MBS6126051-01mL |
MyBiosource |
0.1(mL |
EUR 1350 |
CA125 Cancer Antigen, A Domain (Ovarian Cancer) (AP) |
|
MBS6126051-5x01mL |
MyBiosource |
5x0.1mL |
EUR 5920 |
 (AP)) CA125 Cancer Antigen, B Domain (Ovarian Cancer) (AP) |
|
MBS6126052-01mL |
MyBiosource |
0.1(mL |
EUR 1350 |
CA125 Cancer Antigen, B Domain (Ovarian Cancer) (AP) |
|
MBS6126052-5x01mL |
MyBiosource |
5x0.1mL |
EUR 5920 |
 (PE)) CA125 Cancer Antigen, A Domain (Ovarian Cancer) (PE) |
|
MBS6129145-01mL |
MyBiosource |
0.1(mL |
EUR 1350 |
CA125 Cancer Antigen, A Domain (Ovarian Cancer) (PE) |
|
MBS6129145-5x01mL |
MyBiosource |
5x0.1mL |
EUR 5920 |
 (PE)) CA125 Cancer Antigen, B Domain (Ovarian Cancer) (PE) |
|
MBS6129146-01mL |
MyBiosource |
0.1(mL |
EUR 1350 |
CA125 Cancer Antigen, B Domain (Ovarian Cancer) (PE) |
|
MBS6129146-5x01mL |
MyBiosource |
5x0.1mL |
EUR 5920 |
 (HRP)) CA125 Cancer Antigen, A Domain (Ovarian Cancer) (HRP) |
|
MBS6128524-01mL |
MyBiosource |
0.1(mL |
EUR 1350 |
CA125 Cancer Antigen, A Domain (Ovarian Cancer) (HRP) |
|
MBS6128524-5x01mL |
MyBiosource |
5x0.1mL |
EUR 5920 |
 (HRP)) CA125 Cancer Antigen, B Domain (Ovarian Cancer) (HRP) |
|
MBS6128525-01mL |
MyBiosource |
0.1(mL |
EUR 1350 |
CA125 Cancer Antigen, B Domain (Ovarian Cancer) (HRP) |
|
MBS6128525-5x01mL |
MyBiosource |
5x0.1mL |
EUR 5920 |
 (APC)) CA125 Cancer Antigen, A Domain (Ovarian Cancer) (APC) |
|
MBS6126669-01mL |
MyBiosource |
0.1(mL |
EUR 1350 |
CA125 Cancer Antigen, A Domain (Ovarian Cancer) (APC) |
|
MBS6126669-5x01mL |
MyBiosource |
5x0.1mL |
EUR 5920 |
 (APC)) CA125 Cancer Antigen, B Domain (Ovarian Cancer) (APC) |
|
MBS6126670-01mL |
MyBiosource |
0.1(mL |
EUR 1350 |
CA125 Cancer Antigen, B Domain (Ovarian Cancer) (APC) |
|
MBS6126670-5x01mL |
MyBiosource |
5x0.1mL |
EUR 5920 |
 Partially Purified) Cancer Antigen CA125 (Ovarian Cancer) Partially Purified |
|
MBS313427-100KUnits |
MyBiosource |
100KUnits |
EUR 1235 |
Cancer Antigen CA125 (Ovarian Cancer) Partially Purified |
|
MBS313427-5x100KUnits |
MyBiosource |
5x100KUnits |
EUR 5380 |
 (FITC)) CA125 Cancer Antigen, A Domain (Ovarian Cancer) (FITC) |
|
MBS6127908-01mL |
MyBiosource |
0.1(mL |
EUR 1350 |
CA125 Cancer Antigen, A Domain (Ovarian Cancer) (FITC) |
|
MBS6127908-5x01mL |
MyBiosource |
5x0.1mL |
EUR 5920 |
 (FITC)) CA125 Cancer Antigen, B Domain (Ovarian Cancer) (FITC) |
|
MBS6127909-01mL |
MyBiosource |
0.1(mL |
EUR 1350 |
CA125 Cancer Antigen, B Domain (Ovarian Cancer) (FITC) |
|
MBS6127909-5x01mL |
MyBiosource |
5x0.1mL |
EUR 5920 |
 (PE) (Glycerol Free)) CA125 Cancer Antigen (Ovarian Cancer) (PE) (Glycerol Free) |
|
MBS6120707-01mL |
MyBiosource |
0.1(mL |
EUR 680 |
CA125 Cancer Antigen (Ovarian Cancer) (PE) (Glycerol Free) |
|
MBS6120707-05mL |
MyBiosource |
0.5mL |
EUR 1145 |
CA125 Cancer Antigen (Ovarian Cancer) (PE) (Glycerol Free) |
|
MBS6120707-5x05mL |
MyBiosource |
5x0.5mL |
EUR 4990 |
 (Biotin)) CA125 Cancer Antigen, A Domain (Ovarian Cancer) (Biotin) |
|
MBS6127289-01mL |
MyBiosource |
0.1(mL |
EUR 1350 |
CA125 Cancer Antigen, A Domain (Ovarian Cancer) (Biotin) |
|
MBS6127289-5x01mL |
MyBiosource |
5x0.1mL |
EUR 5920 |
 (Biotin)) CA125 Cancer Antigen, B Domain (Ovarian Cancer) (Biotin) |
|
MBS6127290-01mL |
MyBiosource |
0.1(mL |
EUR 1350 |
CA125 Cancer Antigen, B Domain (Ovarian Cancer) (Biotin) |
|
MBS6127290-5x01mL |
MyBiosource |
5x0.1mL |
EUR 5920 |
 (Glycerol Free) (AP)) CA125 Cancer Antigen (Ovarian Cancer) (Glycerol Free) (AP) |
|
MBS6260254-01mL |
MyBiosource |
0.1mL |
EUR 970 |
CA125 Cancer Antigen (Ovarian Cancer) (Glycerol Free) (AP) |
|
MBS6260254-5x01mL |
MyBiosource |
5x0.1mL |
EUR 4220 |
 (Glycerol Free) (PE)) CA125 Cancer Antigen (Ovarian Cancer) (Glycerol Free) (PE) |
|
MBS6262805-01mL |
MyBiosource |
0.1mL |
EUR 970 |
CA125 Cancer Antigen (Ovarian Cancer) (Glycerol Free) (PE) |
|
MBS6262805-5x01mL |
MyBiosource |
5x0.1mL |
EUR 4220 |
 (Glycerol Free) (HRP)) CA125 Cancer Antigen (Ovarian Cancer) (Glycerol Free) (HRP) |
|
MBS6262295-01mL |
MyBiosource |
0.1mL |
EUR 970 |
CA125 Cancer Antigen (Ovarian Cancer) (Glycerol Free) (HRP) |
|
MBS6262295-5x01mL |
MyBiosource |
5x0.1mL |
EUR 4220 |
 (Glycerol Free) (APC)) CA125 Cancer Antigen (Ovarian Cancer) (Glycerol Free) (APC) |
|
MBS6260765-01mL |
MyBiosource |
0.1mL |
EUR 970 |
CA125 Cancer Antigen (Ovarian Cancer) (Glycerol Free) (APC) |
|
MBS6260765-5x01mL |
MyBiosource |
5x0.1mL |
EUR 4220 |
 (Glycerol Free) (FITC)) CA125 Cancer Antigen (Ovarian Cancer) (Glycerol Free) (FITC) |
|
MBS6261784-01mL |
MyBiosource |
0.1mL |
EUR 970 |
CA125 Cancer Antigen (Ovarian Cancer) (Glycerol Free) (FITC) |
|
MBS6261784-5x01mL |
MyBiosource |
5x0.1mL |
EUR 4220 |
 (Glycerol Free) (Biotin)) CA125 Cancer Antigen (Ovarian Cancer) (Glycerol Free) (Biotin) |
|
MBS6261276-01mL |
MyBiosource |
0.1mL |
EUR 970 |
CA125 Cancer Antigen (Ovarian Cancer) (Glycerol Free) (Biotin) |
|
MBS6261276-5x01mL |
MyBiosource |
5x0.1mL |
EUR 4220 |
 Ovarian cancer associated antigen, Antibody |
|
GWB-A98EF1 |
GenWay Biotech |
0.1 mg |
Ask for price |
 (Glycerol Free) (MaxLight 490)) CA125 Cancer Antigen (Ovarian Cancer) (Glycerol Free) (MaxLight 490) |
|
MBS6263827-01mL |
MyBiosource |
0.1mL |
EUR 970 |
CA125 Cancer Antigen (Ovarian Cancer) (Glycerol Free) (MaxLight 490) |
|
MBS6263827-5x01mL |
MyBiosource |
5x0.1mL |
EUR 4220 |
 (Glycerol Free) (MaxLight 550)) CA125 Cancer Antigen (Ovarian Cancer) (Glycerol Free) (MaxLight 550) |
|
MBS6264338-01mL |
MyBiosource |
0.1mL |
EUR 970 |
CA125 Cancer Antigen (Ovarian Cancer) (Glycerol Free) (MaxLight 550) |
|
MBS6264338-5x01mL |
MyBiosource |
5x0.1mL |
EUR 4220 |
 (Glycerol Free) (MaxLight 650)) CA125 Cancer Antigen (Ovarian Cancer) (Glycerol Free) (MaxLight 650) |
|
MBS6264849-01mL |
MyBiosource |
0.1mL |
EUR 970 |
CA125 Cancer Antigen (Ovarian Cancer) (Glycerol Free) (MaxLight 650) |
|
MBS6264849-5x01mL |
MyBiosource |
5x0.1mL |
EUR 4220 |
 (Glycerol Free) (MaxLight 750)) CA125 Cancer Antigen (Ovarian Cancer) (Glycerol Free) (MaxLight 750) |
|
MBS6265360-01mL |
MyBiosource |
0.1mL |
EUR 970 |
CA125 Cancer Antigen (Ovarian Cancer) (Glycerol Free) (MaxLight 750) |
|
MBS6265360-5x01mL |
MyBiosource |
5x0.1mL |
EUR 4220 |
 (Glycerol Free) (MaxLight 405)) CA125 Cancer Antigen (Ovarian Cancer) (Glycerol Free) (MaxLight 405) |
|
MBS6263316-01mL |
MyBiosource |
0.1mL |
EUR 970 |
CA125 Cancer Antigen (Ovarian Cancer) (Glycerol Free) (MaxLight 405) |
|
MBS6263316-5x01mL |
MyBiosource |
5x0.1mL |
EUR 4220 |
 Mouse anti Ovarian Cancer associated antigen |
|
MBS570442-01mg |
MyBiosource |
0.1mg |
EUR 515 |
Mouse anti Ovarian Cancer associated antigen |
|
MBS570442-5x01mg |
MyBiosource |
5x0.1mg |
EUR 2165 |
 Antibody, Concentrate) CA 125 (Ovarian Cancer Antigen) Antibody, Concentrate |
|
MAB559C |
Innovex |
0.2ml |
EUR 455 |
 ELISA Kit) Cat Ovarian Cancer Antigen X1 (OVX1) ELISA Kit |
|
MBS9351708-INQUIRE |
MyBiosource |
INQUIRE |
Ask for price |
 ELISA Kit) Rat Ovarian Cancer Antigen X1 (OVX1) ELISA Kit |
|
MBS9356185-10x96StripWells |
MyBiosource |
10x96-Strip-Wells |
EUR 6725 |
Rat Ovarian Cancer Antigen X1 (OVX1) ELISA Kit |
|
MBS9356185-48StripWells |
MyBiosource |
48-Strip-Wells |
EUR 550 |
Rat Ovarian Cancer Antigen X1 (OVX1) ELISA Kit |
|
MBS9356185-5x96StripWells |
MyBiosource |
5x96-Strip-Wells |
EUR 3420 |
Rat Ovarian Cancer Antigen X1 (OVX1) ELISA Kit |
|
MBS9356185-96StripWells |
MyBiosource |
96-Strip-Wells |
EUR 765 |
 ELISA Kit) Duck Ovarian Cancer Antigen X1 (OVX1) ELISA Kit |
|
MBS9364449-INQUIRE |
MyBiosource |
INQUIRE |
Ask for price |
 ELISA Kit) Cavy Ovarian Cancer Antigen X1 (OVX1) ELISA Kit |
|
MBS9359316-INQUIRE |
MyBiosource |
INQUIRE |
Ask for price |
 ELISA Kit) Fish Ovarian Cancer Antigen X1 (OVX1) ELISA Kit |
|
MBS9367463-INQUIRE |
MyBiosource |
INQUIRE |
Ask for price |
 ELISA Kit) Goat Ovarian Cancer Antigen X1 (OVX1) ELISA Kit |
|
MBS9356488-INQUIRE |
MyBiosource |
INQUIRE |
Ask for price |
 ELISA Kit) Mouse Ovarian Cancer Antigen X1 (OVX1) ELISA Kit |
|
MBS9351063-10x96StripWells |
MyBiosource |
10x96-Strip-Wells |
EUR 6725 |
Mouse Ovarian Cancer Antigen X1 (OVX1) ELISA Kit |
|
MBS9351063-48StripWells |
MyBiosource |
48-Strip-Wells |
EUR 550 |
Mouse Ovarian Cancer Antigen X1 (OVX1) ELISA Kit |
|
MBS9351063-5x96StripWells |
MyBiosource |
5x96-Strip-Wells |
EUR 3420 |
Mouse Ovarian Cancer Antigen X1 (OVX1) ELISA Kit |
|
MBS9351063-96StripWells |
MyBiosource |
96-Strip-Wells |
EUR 765 |
 ELISA Kit) Camel Ovarian Cancer Antigen X1 (OVX1) ELISA Kit |
|
MBS9351629-10x96StripWells |
MyBiosource |
10x96-Strip-Wells |
EUR 6725 |
Camel Ovarian Cancer Antigen X1 (OVX1) ELISA Kit |
|
MBS9351629-48StripWells |
MyBiosource |
48-Strip-Wells |
EUR 550 |
Camel Ovarian Cancer Antigen X1 (OVX1) ELISA Kit |
|
MBS9351629-5x96StripWells |
MyBiosource |
5x96-Strip-Wells |
EUR 3420 |
Camel Ovarian Cancer Antigen X1 (OVX1) ELISA Kit |
|
MBS9351629-96StripWells |
MyBiosource |
96-Strip-Wells |
EUR 765 |
 ELISA Kit) Horse Ovarian Cancer Antigen X1 (OVX1) ELISA Kit |
|
MBS9355600-10x96StripWells |
MyBiosource |
10x96-Strip-Wells |
EUR 6725 |
Horse Ovarian Cancer Antigen X1 (OVX1) ELISA Kit |
|
MBS9355600-48StripWells |
MyBiosource |
48-Strip-Wells |
EUR 550 |
Horse Ovarian Cancer Antigen X1 (OVX1) ELISA Kit |
|
MBS9355600-5x96StripWells |
MyBiosource |
5x96-Strip-Wells |
EUR 3420 |
Horse Ovarian Cancer Antigen X1 (OVX1) ELISA Kit |
|
MBS9355600-96StripWells |
MyBiosource |
96-Strip-Wells |
EUR 765 |
 ELISA Kit) Sheep Ovarian Cancer Antigen X1 (OVX1) ELISA Kit |
|
MBS9355645-10x96StripWells |
MyBiosource |
10x96-Strip-Wells |
EUR 6725 |
Sheep Ovarian Cancer Antigen X1 (OVX1) ELISA Kit |
|
MBS9355645-48StripWells |
MyBiosource |
48-Strip-Wells |
EUR 550 |
Sheep Ovarian Cancer Antigen X1 (OVX1) ELISA Kit |
|
MBS9355645-5x96StripWells |
MyBiosource |
5x96-Strip-Wells |
EUR 3420 |
Sheep Ovarian Cancer Antigen X1 (OVX1) ELISA Kit |
|
MBS9355645-96StripWells |
MyBiosource |
96-Strip-Wells |
EUR 765 |
 ELISA Kit) Plant Ovarian Cancer Antigen X1 (OVX1) ELISA Kit |
|
MBS9374788-INQUIRE |
MyBiosource |
INQUIRE |
Ask for price |
 ELISA Kit) Goose Ovarian Cancer Antigen X1 (OVX1) ELISA Kit |
|
MBS9344598-INQUIRE |
MyBiosource |
INQUIRE |
Ask for price |
 ELISA Kit) Canine Ovarian Cancer Antigen X1 (OVX1) ELISA Kit |
|
MBS9352149-10x96StripWells |
MyBiosource |
10x96-Strip-Wells |
EUR 6725 |
Canine Ovarian Cancer Antigen X1 (OVX1) ELISA Kit |
|
MBS9352149-48StripWells |
MyBiosource |
48-Strip-Wells |
EUR 550 |
Canine Ovarian Cancer Antigen X1 (OVX1) ELISA Kit |
|
MBS9352149-5x96StripWells |
MyBiosource |
5x96-Strip-Wells |
EUR 3420 |
Canine Ovarian Cancer Antigen X1 (OVX1) ELISA Kit |
|
MBS9352149-96StripWells |
MyBiosource |
96-Strip-Wells |
EUR 765 |
 ELISA Kit) Donkey Ovarian Cancer Antigen X1 (OVX1) ELISA Kit |
|
MBS9362671-INQUIRE |
MyBiosource |
INQUIRE |
Ask for price |
 ELISA Kit) Bovine Ovarian Cancer Antigen X1 (OVX1) ELISA Kit |
|
MBS9364041-10x96StripWells |
MyBiosource |
10x96-Strip-Wells |
EUR 6725 |
Bovine Ovarian Cancer Antigen X1 (OVX1) ELISA Kit |
|
MBS9364041-48StripWells |
MyBiosource |
48-Strip-Wells |
EUR 550 |
Bovine Ovarian Cancer Antigen X1 (OVX1) ELISA Kit |
|
MBS9364041-5x96StripWells |
MyBiosource |
5x96-Strip-Wells |
EUR 3420 |
Bovine Ovarian Cancer Antigen X1 (OVX1) ELISA Kit |
|
MBS9364041-96StripWells |
MyBiosource |
96-Strip-Wells |
EUR 765 |
 ELISA Kit) Pigeon Ovarian Cancer Antigen X1 (OVX1) ELISA Kit |
|
MBS9365415-INQUIRE |
MyBiosource |
INQUIRE |
Ask for price |
 ELISA Kit) Rabbit Ovarian Cancer Antigen X1 (OVX1) ELISA Kit |
|
MBS9352897-INQUIRE |
MyBiosource |
INQUIRE |
Ask for price |
There was no important distinction between the cumulative recurrence incidence curves of the matched teams (P = .319).Laparoscopic surgical procedure for grossly EGC-mimicking AGC is perhaps secure by way of long-term survival final result. After confirming grossly EGC-mimicking AGC within the remaining pathology report, no further surgical procedure is perhaps required.
